Canada markets closed

Metagenomi, Inc. (MGX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.7600-0.0100 (-0.21%)
At close: 04:00PM EDT
4.9200 +0.16 (+3.36%)
After hours: 05:24PM EDT

Metagenomi, Inc.

5959 Horton Street
7th Floor
Emeryville, CA 94608
United States

Full Time Employees237

Key Executives

NameTitlePayExercisedYear Born
Dr. Brian Charles Thomas Ph.D.Co-Founder, CEO & Chairman of the Board859.34kN/A1969
Dr. Jian Irish M.B.A., Ph.D.President, COO & Director729.82kN/A1964
Dr. Sarah B. Noonberg M.D., Ph.D.Chief Medical Officer591.49kN/A1968
Dr. Joseph Knowles M.D.Co-Founder & Member of Scientific Advisory BoardN/AN/AN/A
Ms. Pamela M. Wapnick M.B.A.Chief Financial OfficerN/AN/A1966
Mr. Simon Harnest M.Sc.Chief Investment Officer & Senior VP of Investor RelationsN/AN/A1987
Mr. Matthew L. Wein J.D.Vice President of Corporate Legal, Compliance & Corporate SecretaryN/AN/A1971
Dr. Alan Brooks Ph.D.Senior Vice President of PreclinicalN/AN/A1966
Dr. Christopher BrownHead of DiscoveryN/AN/A1989
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Corporate Governance

Metagenomi, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.